Jefferies Turns Bullish on COR with 12% Upside Potential

Investment bank Jefferies recently upgraded Cencora (COR) from a Hold rating to Buy, signaling renewed confidence in the healthcare distribution giant. This shift reflects growing optimism about the company’s near-term prospects and comes at a time when institutional investors are closely monitoring the stock’s performance.

Price Target Signals Strong Growth Potential

As of mid-January 2026, Wall Street analysts have set an average one-year price target of $396.17 per share for COR, representing approximately 12.40% upside from the stock’s latest closing price of $352.45. The consensus forecasts range considerably, with estimates spanning from $305.47 on the conservative end to $462.00 on the bullish side. This $90.52 band between high and low targets underscores the varying views on COR’s trajectory.

Beyond valuation metrics, analysts project Cencora’s annual revenue at $298.3 billion, though this represents a 7.18% decline from previous expectations. The projected non-GAAP earnings per share stands at $15.12, suggesting the market remains focused on operational profitability despite anticipated revenue headwinds.

Institutional Investors Show Mixed Sentiment

The fund sentiment surrounding COR presents an intriguing picture. Approximately 2,379 funds and institutions maintain positions in the company, reflecting slight portfolio repositioning with a net decline of 30 owners (1.25%) during the most recent quarter. The average portfolio allocation to COR across all institutional investors is 0.36%, marking a 5.95% increase in relative weight.

More significantly, total institutional shareholding increased by 0.77% to 217.8 million shares over the past three months. The put/call ratio for COR stands at 0.62, indicating that options traders are pricing in a bullish outlook with calls outnumbering puts—a constructive technical signal.

Major Holders Adjust Positions Amid Market Optimism

Among COR’s largest institutional shareholders, activity patterns reveal nuanced positioning strategies. T. Rowe Price Associates, which holds 7.72 million shares (3.98% ownership), trimmed its position by 0.91% compared to its prior quarter filing, from 7.795 million shares. Despite this reduction, the asset manager decreased its COR portfolio allocation by a more substantial 50.64% over the quarterly period.

Walgreens Boots Alliance, the pharmacy retailer and another major stakeholder, holds 7.47 million shares representing 3.85% of COR’s outstanding equity. The company made more significant cuts to its COR position, reducing holdings by 38.90% from 10.38 million shares in the prior filing. Interestingly, despite the absolute reduction, Walgreens slightly increased its relative portfolio weight in COR by 7.04%.

Index funds continue to build exposure to COR. Vanguard’s Total Stock Market Index Fund holds 5.91 million shares (3.04% ownership), up 6.67% from the prior quarter’s 5.51 million shares, with a corresponding 3.08% increase in portfolio allocation. Similarly, Vanguard’s 500 Index Fund maintains 4.90 million shares (2.52% ownership), adding 2.07% to its position while marginally reducing relative portfolio weight by 2.18%.

Geode Capital Management, another major institutional player, expanded its COR stake by 9.50% to 5.29 million shares (2.73% ownership) from the prior quarter’s 4.79 million shares. However, the firm simultaneously decreased its COR portfolio allocation by 44.30%, a divergence likely reflecting broader portfolio rebalancing activities.

The aggregate institutional activity suggests confidence in COR’s long-term prospects despite some profit-taking at certain positions. Jefferies’ upgrade appears well-timed given the modest but growing institutional commitment to the stock.